

# Quarterly Camelid TB Serology Report for 2025 - Qtr 3

Year, Quarter

2025 (Year) + Qtr 3 (Qua...

▼

## Number of Samples Tested and Submission Reason 2025 - Qtr 3

Table 1a

| Country   | No. Samples Tested |
|-----------|--------------------|
| England   | 111                |
| Non GB    | 0                  |
| Not Known | 3                  |
| Scotland  | 0                  |
| Wales     | 113                |
| Total     | 227                |

Table 1b

| Project Group                         | No. Samples Tested |
|---------------------------------------|--------------------|
| <div>Commercial/Private Testing</div> | 3                  |
| SER-DIAG                              | 0                  |
| SER-EXP                               | 0                  |
| SER-MVT                               | 3                  |
| SER-RHT                               | 0                  |
| <div>Other</div>                      | 2                  |
|                                       | 0                  |
| PME                                   | 0                  |
| SER-SUS                               | 2                  |
| TB_DIAG                               | 0                  |
| TB_REACT                              | 0                  |
| <div>Parallel</div>                   | 0                  |
| PAR-COL-W                             | 0                  |
| PAR-TB                                | 0                  |
| PAR-TRC                               | 0                  |
| <div>Serial</div>                     | 222                |
| SER-CHK                               | 0                  |
| SER-COL                               | 0                  |
| SER-CONT                              | 201                |
| SER-EPI                               | 21                 |
| Total                                 | 227                |

# Quarterly Camelid TB Serology Report for 2025 YTD

Year, Quarter

Multiple selections

▼

## Number of Samples Tested and Submission Reason 2025 to the end of Qtr 3

Table 2a

| Country   | No. Samples Tested |
|-----------|--------------------|
| England   | 471                |
| Non GB    | 0                  |
| Not Known | 5                  |
| Scotland  | 0                  |
| Wales     | 160                |
| Total     | 636                |

Table 2b

| Project Group                                    | No. Samples Tested |
|--------------------------------------------------|--------------------|
| <div><div></div>Commercial/Private Testing</div> | 11                 |
| SER-DIAG                                         | 0                  |
| SER-EXP                                          | 0                  |
| SER-MVT                                          | 11                 |
| SER-RHT                                          | 0                  |
| <div><div></div>Other</div>                      | 62                 |
|                                                  | 0                  |
| PME                                              | 0                  |
| SER-SUS                                          | 62                 |
| TB_DIAG                                          | 0                  |
| TB_REACT                                         | 0                  |
| <div><div></div>Parallel</div>                   | 12                 |
| PAR-COL-W                                        | 0                  |
| PAR-TB                                           | 12                 |
| PAR-TRC                                          | 0                  |
| <div><div></div>Serial</div>                     | 551                |
| SER-CHK                                          | 1                  |
| SER-COL                                          | 32                 |
| SER-CONT                                         | 495                |
| SER-EPI                                          | 23                 |
| Total                                            | 636                |

# Quarterly Camelid TB Serology Report for 2025 - Qtr 3

Year, Quarter

2025 (Year) + Qtr 3 (Qua... ▼

## Test Positivity in 2025 - Qtr 3

Table 3

| Country                                          | No. Submissions | No. Samples Tested | No. Positive Samples | % Positive Samples |
|--------------------------------------------------|-----------------|--------------------|----------------------|--------------------|
| <div><div></div>England</div>                    | 13              | 111                | 1                    | 0.9 %              |
| <div><div></div>Commercial/Private Testing</div> | 0               | 0                  | 0                    | NaN                |
| SER-DIAG                                         | 0               | 0                  | 0                    | NaN                |
| SER-EXP                                          | 0               | 0                  | 0                    | NaN                |
| SER-MVT                                          | 0               | 0                  | 0                    | NaN                |
| SER-RHT                                          | 0               | 0                  | 0                    | NaN                |
| <div><div></div>Other</div>                      | 1               | 2                  | 0                    | 0.0 %              |
|                                                  | 0               | 0                  | 0                    | NaN                |
| PME                                              | 0               | 0                  | 0                    | NaN                |
| SER-SUS                                          | 1               | 2                  | 0                    | 0.0 %              |
| TB_DIAG                                          | 0               | 0                  | 0                    | NaN                |
| TB_REACT                                         | 0               | 0                  | 0                    | NaN                |
| <div><div></div>Parallel</div>                   | 0               | 0                  | 0                    | NaN                |
| PAR-TB                                           | 0               | 0                  | 0                    | NaN                |
| PAR-TRC                                          | 0               | 0                  | 0                    | NaN                |
| <div><div></div>Serial</div>                     | 12              | 109                | 1                    | 0.9 %              |
| SER-CHK                                          | 0               | 0                  | 0                    | NaN                |
| SER-COL                                          | 0               | 0                  | 0                    | NaN                |
| SER-CONT                                         | 11              | 88                 | 1                    | 1.1 %              |
| SER-EPI                                          | 1               | 21                 | 0                    | 0.0 %              |
| <div><div></div>Non GB</div>                     | 0               | 0                  | 0                    | NaN                |
| <div><div></div>Other</div>                      | 0               | 0                  | 0                    | NaN                |
|                                                  | 0               | 0                  | 0                    | NaN                |
| <div><div></div>Not Known</div>                  | 1               | 3                  | 0                    | 0.0 %              |
| <div><div></div>Commercial/Private Testing</div> | 1               | 3                  | 0                    | 0.0 %              |
| SER-MVT                                          | 1               | 3                  | 0                    | 0.0 %              |
| <div><div></div>Other</div>                      | 0               | 0                  | 0                    | NaN                |
|                                                  | 0               | 0                  | 0                    | NaN                |
| <div><div></div>Parallel</div>                   | 0               | 0                  | 0                    | NaN                |
| PAR-TB                                           | 0               | 0                  | 0                    | NaN                |
| <div><div></div>Scotland</div>                   | 0               | 0                  | 0                    | NaN                |
| <div><div></div>Commercial/Private Testing</div> | 0               | 0                  | 0                    | NaN                |
| SER-EXP                                          | 0               | 0                  | 0                    | NaN                |
| SER-MVT                                          | 0               | 0                  | 0                    | NaN                |
| <div><div></div>Other</div>                      | 0               | 0                  | 0                    | NaN                |
|                                                  | 0               | 0                  | 0                    | NaN                |
| TB_REACT                                         | 0               | 0                  | 0                    | NaN                |
| <div><div></div>Wales</div>                      | 5               | 113                | 1                    | 0.9 %              |
| <div><div></div>Other</div>                      | 0               | 0                  | 0                    | NaN                |
|                                                  | 0               | 0                  | 0                    | NaN                |
| PME                                              | 0               | 0                  | 0                    | NaN                |
| SER-SUS                                          | 0               | 0                  | 0                    | NaN                |
| TB_REACT                                         | 0               | 0                  | 0                    | NaN                |
| <div><div></div>Parallel</div>                   | 0               | 0                  | 0                    | NaN                |
| PAR-COL-W                                        | 0               | 0                  | 0                    | NaN                |
| PAR-TB                                           | 0               | 0                  | 0                    | NaN                |
| <div><div></div>Serial</div>                     | 5               | 113                | 1                    | 0.9 %              |
| SER-COL                                          | 0               | 0                  | 0                    | NaN                |
| SER-CONT                                         | 5               | 113                | 1                    | 0.9 %              |
| SER-EPI                                          | 0               | 0                  | 0                    | NaN                |
| Total                                            | 19              | 227                | 2                    | 0.9 %              |

# Quarterly Camelid TB Serology Report for 2025 YTD

Year, Quarter

Multiple selections 

## Test Positivity in 2025 to the end of Qtr 3

Table 3

| Country                                                                                                               | No. Submissions | No. Samples Tested | No. Positive Samples | % Positive Samples |
|-----------------------------------------------------------------------------------------------------------------------|-----------------|--------------------|----------------------|--------------------|
|  <b>England</b>                      | <b>55</b>       | <b>471</b>         | <b>3</b>             | <b>0.6 %</b>       |
|  <b>Commercial/Private Testing</b>   | <b>2</b>        | <b>8</b>           | <b>0</b>             | <b>0.0 %</b>       |
| SER-DIAG                                                                                                              | 0               | 0                  | 0                    | NaN                |
| SER-EXP                                                                                                               | 0               | 0                  | 0                    | NaN                |
| SER-MVT                                                                                                               | 2               | 8                  | 0                    | 0.0 %              |
| SER-RHT                                                                                                               | 0               | 0                  | 0                    | NaN                |
|  <b>Other</b>                        | <b>3</b>        | <b>62</b>          | <b>0</b>             | <b>0.0 %</b>       |
|                                                                                                                       | 0               | 0                  | 0                    | NaN                |
| PME                                                                                                                   | 0               | 0                  | 0                    | NaN                |
| SER-SUS                                                                                                               | 3               | 62                 | 0                    | 0.0 %              |
| TB_DIAG                                                                                                               | 0               | 0                  | 0                    | NaN                |
| TB_REACT                                                                                                              | 0               | 0                  | 0                    | NaN                |
|  <b>Parallel</b>                     | <b>3</b>        | <b>10</b>          | <b>0</b>             | <b>0.0 %</b>       |
| PAR-TB                                                                                                                | 3               | 10                 | 0                    | 0.0 %              |
| PAR-TRC                                                                                                               | 0               | 0                  | 0                    | NaN                |
|  <b>Serial</b>                       | <b>47</b>       | <b>391</b>         | <b>3</b>             | <b>0.8 %</b>       |
| SER-CHK                                                                                                               | 1               | 1                  | 0                    | 0.0 %              |
| SER-COL                                                                                                               | 5               | 32                 | 0                    | 0.0 %              |
| SER-CONT                                                                                                              | 39              | 335                | 3                    | 0.9 %              |
| SER-EPI                                                                                                               | 2               | 23                 | 0                    | 0.0 %              |
|  <b>Non GB</b>                     | <b>0</b>        | <b>0</b>           | <b>0</b>             | <b>NaN</b>         |
|  <b>Other</b>                      | <b>0</b>        | <b>0</b>           | <b>0</b>             | <b>NaN</b>         |
|                                                                                                                       | 0               | 0                  | 0                    | NaN                |
|  <b>Not Known</b>                  | <b>2</b>        | <b>5</b>           | <b>0</b>             | <b>0.0 %</b>       |
|  <b>Commercial/Private Testing</b> | <b>1</b>        | <b>3</b>           | <b>0</b>             | <b>0.0 %</b>       |
| SER-MVT                                                                                                               | 1               | 3                  | 0                    | 0.0 %              |
|  <b>Other</b>                      | <b>0</b>        | <b>0</b>           | <b>0</b>             | <b>NaN</b>         |
|                                                                                                                       | 0               | 0                  | 0                    | NaN                |
|  <b>Parallel</b>                   | <b>1</b>        | <b>2</b>           | <b>0</b>             | <b>0.0 %</b>       |
| PAR-TB                                                                                                                | 1               | 2                  | 0                    | 0.0 %              |
|  <b>Scotland</b>                   | <b>0</b>        | <b>0</b>           | <b>0</b>             | <b>NaN</b>         |
|  <b>Commercial/Private Testing</b> | <b>0</b>        | <b>0</b>           | <b>0</b>             | <b>NaN</b>         |
| SER-EXP                                                                                                               | 0               | 0                  | 0                    | NaN                |
| SER-MVT                                                                                                               | 0               | 0                  | 0                    | NaN                |
|  <b>Other</b>                      | <b>0</b>        | <b>0</b>           | <b>0</b>             | <b>NaN</b>         |
|                                                                                                                       | 0               | 0                  | 0                    | NaN                |
| TB_REACT                                                                                                              | 0               | 0                  | 0                    | NaN                |
|  <b>Wales</b>                      | <b>11</b>       | <b>160</b>         | <b>2</b>             | <b>1.3 %</b>       |
|  <b>Other</b>                      | <b>0</b>        | <b>0</b>           | <b>0</b>             | <b>NaN</b>         |
|                                                                                                                       | 0               | 0                  | 0                    | NaN                |
| PME                                                                                                                   | 0               | 0                  | 0                    | NaN                |
| SER-SUS                                                                                                               | 0               | 0                  | 0                    | NaN                |
| TB_REACT                                                                                                              | 0               | 0                  | 0                    | NaN                |
|  <b>Parallel</b>                   | <b>0</b>        | <b>0</b>           | <b>0</b>             | <b>NaN</b>         |
| PAR-COL-W                                                                                                             | 0               | 0                  | 0                    | NaN                |
| PAR-TB                                                                                                                | 0               | 0                  | 0                    | NaN                |
|  <b>Serial</b>                     | <b>11</b>       | <b>160</b>         | <b>2</b>             | <b>1.3 %</b>       |
| SER-COL                                                                                                               | 0               | 0                  | 0                    | NaN                |
| SER-CONT                                                                                                              | 11              | 160                | 2                    | 1.3 %              |
| SER-EPI                                                                                                               | 0               | 0                  | 0                    | NaN                |
| <b>Total</b>                                                                                                          | <b>68</b>       | <b>636</b>         | <b>5</b>             | <b>0.8 %</b>       |

# Quarterly Camelid TB Serology Report for 2025 - Qtr 3

Year, Quarter

2025 (Year) + Qtr 3 (Qua... ▼

Table 5: Number of samples Tested by Test Code

Numbers not reflective of total number of samples tested due to test being used in combination

| Year                                               | 2025  |       |
|----------------------------------------------------|-------|-------|
| ANALYSIS                                           | Qtr 3 | Total |
| TC0603                                             |       |       |
| Camelid TB Enferplex - 4 Spot                      | 72    | 72    |
| TC0611                                             |       |       |
| Chembio DPP VetTB lateral flow rapid antibody test | 153   | 153   |
| TC0867                                             |       |       |
| Camelid TB Antibody ELISA                          | 153   | 153   |

**Test Criteria**

**Submission Reason & Explanation**

**APHA /DEFRA:** At Government expense

**Parallel Test:**

**PAR-TB TB:** breakdown herd with confirmed M. bovis infection (including Wales where Officially TB Free Withdrawn [OTFW] status is determined on epidemiological grounds

**PAR-TRC:** Forward tracing(s) from an M. bovis-infected camelid herd (includes camelid herds in Wales only co-located on the same premises with infected cattle, sheep, deer, goats & pigs)

**PAR-COL-W:** Wales only - camelids under restriction due to sharing a holding (colocation) with an OTFW cattle herd or with other non-bovine animals affected by a culture-confirmed incident

**Serial Test:**

**SER-SUS:** (replaces PAR-SUS) TB strongly suspected but not currently confirmed by laboratory culture – herd under restrictions. If infection is confirmed the initial High Specificity (serial) test results can be reinterpreted at High Sensitivity on request from the APHA case vet.

**SER-CONT:** Herd not under restriction but contiguous to a TB-infected herd

**SER-COL:** Herd not under restriction but co-located with an infected herd of cattle, deer, goats etc. (Eng & Scot only)

**SER-EPI:** Herd not under restriction but TB tested due to an epidemiological link with a known infected herd (e.g. back-tracing)

**SER-CHK:** Inconclusive Reactor check test – e.g. where private Enferplex test has produced a 2-spot-positive result on 2 consecutive occasions

**Commercial/Private:** At Owner expense

**SER-MVT:** Pre- or post-movement test

**SER-EXP:** Pre-export test

The camelid TB serology (antibody) test generally comprises two separate antibody tests in a test package that can be applied flexibly to increase the sensitivity or specificity of the test as required, by using a parallel or serial test interpretation respectively. The sensitivity and specificity values of combined antibody testing for camelids were described under AHVLA Project FT1477 (see Rhodes et al., 2012) and re-assessed in May 2018 to show the following test performance;

**Table 1 – High Sensitivity / Parallel test options:**

|                               | <b>% Se</b> | <b>95% C.I.</b> | <b>% Sp</b> | <b>95% C.I.</b> |
|-------------------------------|-------------|-----------------|-------------|-----------------|
| <b>IDEXX /DPP VetTB</b>       | 74          | 65.4-82.6       | 96          | 93.8-98.2       |
| <b>ENFER 2-SPOT/DPP VetTB</b> | 71          | 62.1-79.9       | 96.7        | 95.8-99.4       |
| <b>IDEXX/ENFER 2-SPOT</b>     | 75          | 66.5-83.5       | 97.3        | 95.4-99.1       |

Fishers Exact [2-sided] test showed no significant difference in sensitivity or specificity between any of these three test options.

**Table 2 – High Specificity / Serial test options:**

|                        | <b>% Se</b> | <b>95% C.I.</b> | <b>% Sp</b> | <b>95% C.I.</b> |
|------------------------|-------------|-----------------|-------------|-----------------|
| <b>ENFER 4-SPOT</b>    | 60          | 50.4-69.9       | 99.66       | 98.9-100        |
| <b>IDEXX/DPP VetTB</b> | 56          | 46.3-65.7       | 100         |                 |

Fishers Exact [2-sided] test showed no significant difference in test sensitivity or specificity between these two test options.

Rhodes, S., Holder, T., Clifford, D., Dexter, I., Brewer, J., Smith, N., Waring, L., Crawshaw, T., Gillgan, S., Lyashchenko, K., Lawrence, J., Clarke, J., de la Rua-Domenech, R., Vordermeier, M., 2012. Evaluation of gamma interferon and antibody tuberculosis tests in alpacas. Clin Vaccine Immunol 19, 1677-1683.